Teleflex Incorporated (TFX) Expected to Post Earnings of $2.02 Per Share
Equities research analysts expect Teleflex Incorporated (NYSE:TFX) to report $2.02 earnings per share for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for Teleflex’s earnings, with the highest EPS estimate coming in at $2.08 and the lowest estimate coming in at $1.98. Teleflex reported earnings per share of $1.80 during the same quarter last year, which would indicate a positive year over year growth rate of 12.2%. The company is expected to issue its next earnings report on Thursday, October 26th.
On average, analysts expect that Teleflex will report full year earnings of $8.29 per share for the current year, with EPS estimates ranging from $8.18 to $8.35. For the next financial year, analysts expect that the business will post earnings of $9.67 per share, with EPS estimates ranging from $9.54 to $9.94. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Teleflex.
Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, August 3rd. The medical technology company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.13. The business had revenue of $528.60 million during the quarter, compared to the consensus estimate of $518.98 million. Teleflex had a return on equity of 16.12% and a net margin of 12.36%. The firm’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.89 earnings per share.
TFX has been the subject of a number of research analyst reports. Zacks Investment Research lowered Teleflex from a “buy” rating to a “hold” rating in a research report on Thursday, August 31st. Leerink Swann raised Teleflex from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $227.00 to $266.00 in a research report on Thursday, September 7th. Barclays PLC reaffirmed a “buy” rating on shares of Teleflex in a research report on Monday, June 26th. Deutsche Bank AG reaffirmed a “buy” rating and set a $238.00 target price (up from $220.00) on shares of Teleflex in a research report on Wednesday, August 9th. Finally, Jefferies Group LLC lifted their target price on Teleflex from $253.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, September 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the stock. Teleflex currently has a consensus rating of “Buy” and an average price target of $260.75.
In other news, Director Stephen K. M.D. Klasko sold 200 shares of the business’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $241.88, for a total value of $48,376.00. Following the completion of the transaction, the director now directly owns 8,080 shares of the company’s stock, valued at approximately $1,954,390.40. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Over the last three months, insiders sold 600 shares of company stock valued at $132,408. Corporate insiders own 2.39% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Atlanta Capital Management Co. L L C raised its position in shares of Teleflex by 2.6% in the 2nd quarter. Atlanta Capital Management Co. L L C now owns 2,519,464 shares of the medical technology company’s stock worth $523,444,000 after acquiring an additional 64,985 shares in the last quarter. Janus Henderson Group PLC raised its position in shares of Teleflex by 50,429.2% in the 2nd quarter. Janus Henderson Group PLC now owns 1,816,020 shares of the medical technology company’s stock worth $377,296,000 after acquiring an additional 1,812,426 shares in the last quarter. State Street Corp raised its position in shares of Teleflex by 1.8% in the 2nd quarter. State Street Corp now owns 1,399,922 shares of the medical technology company’s stock worth $290,853,000 after acquiring an additional 25,401 shares in the last quarter. Koch Industries Inc. raised its position in shares of Teleflex by 47,174.3% in the 2nd quarter. Koch Industries Inc. now owns 959,669 shares of the medical technology company’s stock worth $955,000 after acquiring an additional 957,639 shares in the last quarter. Finally, American Century Companies Inc. raised its position in shares of Teleflex by 22.8% in the 2nd quarter. American Century Companies Inc. now owns 839,080 shares of the medical technology company’s stock worth $174,327,000 after acquiring an additional 155,863 shares in the last quarter. 89.75% of the stock is owned by hedge funds and other institutional investors.
Teleflex (NYSE TFX) opened at 240.76 on Wednesday. Teleflex has a 12-month low of $136.53 and a 12-month high of $248.68. The firm has a 50-day moving average price of $233.66 and a 200-day moving average price of $211.26. The company has a market cap of $10.84 billion, a P/E ratio of 46.04 and a beta of 1.07.
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.